UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 159

Sortiert nach

The Group of Treatment Resistant Schizophrenias. Heterogeneity in Treatment Resistant Schizophrenia (TRS)

Frontiers in psychiatry, 2019-01, Vol.9, p.757-757

Kinon, Bruce J

2019

Volltextzugriff (PDF)

Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia

Biological psychiatry (1969), 2015-12, Vol.78 (11), p.754-762

2015

Volltextzugriff (PDF)

Improving Translational Relevance in Preclinical Psychopharmacology (iTRIPP)

Journal of psychopharmacology (Oxford), 2023-11, Vol.37 (11), p.1051-1057

2023

Volltextzugriff (PDF)

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia

BMC psychiatry, 2013-05, Vol.13 (1), p.143-143, Article 143

2013

Volltextzugriff (PDF)

A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

Journal of clinical psychopharmacology, 2011-06, Vol.31 (3), p.349-355

2011

Volltextzugriff (PDF)

Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia

Neuropsychopharmacology (New York, N.Y.), 2010-01, Vol.35 (2), p.581-590

2010

Volltextzugriff (PDF)

A predictor model of treatment resistance in schizophrenia using data from electronic health records

PloS one, 2022-09, Vol.17 (9), p.e0274864

2022

Volltextzugriff (PDF)

Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine

Journal of psychopharmacology (Oxford), 2022-04, Vol.36 (4), p.498-506

2022

Volltextzugriff (PDF)

Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs

BMC medicine, 2005-12, Vol.3 (1), p.21-21, Article 21

2005

Volltextzugriff (PDF)

Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo

Schizophrenia research, 2013-11, Vol.150 (2), p.434-441

2013

Volltextzugriff (PDF)

Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension

Schizophrenia research, 2022-10, Vol.248, p.271-278

2022

Volltextzugriff (PDF)

Dynamic ElecTronic hEalth reCord deTection (DETECT) of individuals at risk of a first episode of psychosis: a case-control development and validation study

The Lancet. Digital health, 2020-05, Vol.2 (5), p.e229-e239

2020

Volltextzugriff (PDF)

Clinical correlates of early onset antipsychotic treatment resistance

Journal of psychopharmacology (Oxford), 2022-11, Vol.36 (11), p.1226-1233

2022

Volltextzugriff (PDF)

Transdiagnostic individualized clinically-based risk calculator for the automatic detection of individuals at-risk and the prediction of psychosis: external replication in 2,430,333 US patients

Translational psychiatry, 2020-10, Vol.10 (1), p.364-364, Article 364

2020

Volltextzugriff (PDF)

Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials

The journal of clinical psychiatry, 2014-04, Vol.75 (4), p.e308

2014

Volltextzugriff (PDF)

The burden of depressive symptoms in the long-term treatment of patients with schizophrenia

Schizophrenia research, 2007-02, Vol.90 (1), p.186-197

2007

Volltextzugriff (PDF)

Clinical development of pomaglumetad methionil: A non-dopaminergic treatment for schizophrenia

Neuropharmacology, 2013-03, Vol.66, p.82-86

2013

Volltextzugriff (PDF)

Negative symptoms in schizophrenia – the remarkable impact of inclusion definitions in clinical trials and their consequences

Schizophrenia research, 2013-11, Vol.150 (2), p.334-338

2013

Volltextzugriff (PDF)

A machine-learning framework for robust and reliable prediction of short- and long-term treatment response in initially antipsychotic-naïve schizophrenia patients based on multimodal neuropsychiatric data

Translational psychiatry, 2020-08, Vol.10 (1), p.276-276, Article 276

2020

Volltextzugriff (PDF)

A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia

BMC psychiatry, 2014-12, Vol.14 (1), p.351-351, Article 351

2014

Volltextzugriff (PDF)

Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects

Psychopharmacology, 2018-07, Vol.235 (7), p.1875-1886

2018

Volltextzugriff (PDF)

Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia

Schizophrenia research, 2008-07, Vol.102 (1), p.230-240

2008

Volltextzugriff (PDF)

Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response

The journal of clinical psychiatry, 2009-07, Vol.70 (7), p.990

2009

Volltextzugriff (PDF)

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia

Schizophrenia bulletin, 2008-11, Vol.34 (6), p.1163-1171

2008

Volltextzugriff (PDF)

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia

The journal of clinical psychiatry, 2001-02, Vol.62 (2), p.92

2001

Volltextzugriff (PDF)

1 – 25 von 159

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(156)
Mit Volltextzugriff
(145)

Publikationsform

Sprache

Englisch
(159)
Japanisch
(14)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(114)
Life Sciences & Biomedicine
(112)
Psychiatry
(106)
Humans
(102)
Schizophrenia
(82)
Male
(76)
Schizophrenia - Drug Therapy
(75)
Female
(74)
Antipsychotic Agents - Therapeutic Use
(72)
Adult
(66)
Treatment Outcome
(50)
Biological And Medical Sciences
(47)
Medical Sciences
(47)
Middle Aged
(42)
Pharmacology & Pharmacy
(42)
Psychology. Psychoanalysis. Psychiatry
(41)
Pharmacology. Drug Treatments
(36)
Psychiatric Status Rating Scales
(34)
Schizophrenic Psychology
(34)
Antipsychotic Agents - Adverse Effects
(33)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Group of Treatment Resistant Schizophrenias. Heterogeneity in Treatment Resistant Schizophrenia (TRS)

Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia

Improving Translational Relevance in Preclinical Psychopharmacology (iTRIPP)

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia

A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia

A predictor model of treatment resistance in schizophrenia using data from electronic health records

Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine

Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs

Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo

Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension

Dynamic ElecTronic hEalth reCord deTection (DETECT) of individuals at risk of a first episode of psychosis: a case-control development and validation study

Clinical correlates of early onset antipsychotic treatment resistance

Transdiagnostic individualized clinically-based risk calculator for the automatic detection of individuals at-risk and the prediction of psychosis: external replication in 2,430,333 US patients

Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials

The burden of depressive symptoms in the long-term treatment of patients with schizophrenia

Clinical development of pomaglumetad methionil: A non-dopaminergic treatment for schizophrenia

Negative symptoms in schizophrenia – the remarkable impact of inclusion definitions in clinical trials and their consequences

A machine-learning framework for robust and reliable prediction of short- and long-term treatment response in initially antipsychotic-naïve schizophrenia patients based on multimodal neuropsychiatric data

A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia

Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects

Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia

Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia

Suchergebnisse filtern